Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 1

Oxybutynin: an overview of the available formulations

Authors Rebecca J McCrery, Rodney A Appell

Published 15 March 2006 Volume 2006:2(1) Pages 19—24

Rebecca J McCrery, Rodney A Appell

Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA

Abstract: Overactive bladder (OAB) is a common problem presented to by physicians. Standard treatment with antimuscarinic medication is directed at suppressing involuntary detrusor contractions by blocking the binding of acetylcholine to muscarinic receptors in the bladder. Oxybutynin chloride is the first of several antimuscarinic medications to be marketed for OAB. Although efficacious for treating OAB symptoms, the side effects and suboptimal dosing regimen decrease its utility. To improve patient compliance and tolerability, alternative delivery systems for oxybutynin have subsequently been developed and include a once-daily formulation and a transdermal system. The currently available formulations of oxybutynin are the subject of this review.


Keywords: overactive bladder, antimuscarinic, urinary incontinence, detrusor overactivity

Download Article [PDF] 

Readers of this article also read:

Engineering practice variation through provider agreement: a cluster-randomized feasibility trial

McCarren M, Twedt EL, Mansuri FM, Nelson PR, Peek BT

Therapeutics and Clinical Risk Management 2014, 10:905-912

Published Date: 28 October 2014

Prediction and prevention of the first psychotic episode: new directions and opportunities

Piras S, Casu G, Casu MA, Orrù A, Ruiu S, Pilleri A, Manca G, Marchese G

Therapeutics and Clinical Risk Management 2014, 10:241-253

Published Date: 28 March 2014

Portal vein thrombosis in a patient with HCV cirrhosis and combined hemophilia A and thrombophilia V Leiden

Nikos Eleftheriadis, Pantelis Makris

Therapeutics and Clinical Risk Management 2010, 6:539-541

Published Date: 26 October 2010

Potential bias in ophthalmic pharmaceutical clinical trials

Paul Varner

Clinical Ophthalmology 2008, 2:401-411

Published Date: 6 June 2008

Acne phototherapy with a 1450-nm diode laser: an open study

Natusko Konishi, Hideki Endo, Naoki Oiso, Shigeru Kawara, Akira Kawada

Therapeutics and Clinical Risk Management 2007, 3:205-209

Published Date: 15 March 2007